KAPLAN PHARMACOLOGY I EXAMINATION QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS)
PLUS RATIONALES 2026 Q&A | LATEST EXAM UPDATE 2026/2027.
Core Domains:
Pharmacokinetics (ADME)
Pharmacodynamics (Receptor Theory & Dose-Response)
Autonomic Nervous System Pharmacology
Cardiovascular & Renal Pharmacology
Central Nervous System Pharmacology
Endocrine Pharmacology
Antimicrobial & Chemotherapeutic Agents
Toxicology & Adverse Drug Reactions
Pharmacogenomics & Drug Interactions
Legal, Ethical, and Professional Standards in Prescribing
Introduction:
This comprehensive assessment is designed to rigorously evaluate the candidate's mastery of fundamental
pharmacological principles as outlined in the Kaplan Pharmacology I curriculum. The examination measures both
foundational knowledge of drug mechanisms and the application of clinical decision-making in complex patient
scenarios. Through a series of multiple-choice questions and case-based presentations, candidates will be
,challenged to integrate pharmacodynamic and pharmacokinetic concepts with legal, ethical, and professional
standards of care. The emphasis is on real-world application, requiring the candidate to prioritize patient safety,
recognize adverse drug reactions, and formulate evidence-based therapeutic plans. Successful completion of this
assessment demonstrates readiness for advanced clinical practice and standardized examination preparation.
SECTION ONE: QUESTIONS 1–50
1. A patient with a history of chronic liver disease is prescribed a medication with high hepatic extraction.
Which pharmacokinetic parameter is MOST significantly altered in this patient, leading to a marked increase
in drug bioavailability?
A. Volume of distribution
B. Renal clearance
C. First-pass metabolism
D. Plasma protein binding
🟢 C. First-pass metabolism
🔴 RATIONALE: Drugs with high hepatic extraction undergo extensive first-pass metabolism, significantly
reducing their bioavailability. In liver disease, hepatic blood flow and metabolic enzyme function decrease,
reducing this effect and leading to a marked increase in bioavailability. Volume of distribution is more affected
by protein binding and body composition, not directly the primary cause of this increased bioavailability. Renal
clearance primarily affects drugs excreted by the kidneys. While plasma protein binding can be altered, the
primary mechanism for this change in bioavailability is the reduction in first-pass metabolism.
, 2. A new drug is being developed that acts as a non-competitive antagonist at a specific receptor. In the
presence of this drug, which change in the dose-response curve for the endogenous agonist is MOST likely
observed?
A. Parallel shift to the right with no change in maximum effect
B. Non-parallel shift to the right with a decreased maximum effect
C. Parallel shift to the left with no change in maximum effect
D. Non-parallel shift to the right with an increased maximum effect
🟢 B. Non-parallel shift to the right with a decreased maximum effect
🔴 RATIONALE: Non-competitive antagonists bind to an allosteric site on the receptor, effectively reducing the
number of available receptors. This results in a non-parallel shift to the right of the dose-response curve and,
most importantly, a reduction in the maximum achievable effect (Emax). A competitive antagonist (A) causes a
parallel shift to the right with no change in Emax.
3. An 80-year-old patient with renal impairment is prescribed a medication primarily cleared by the kidneys.
The prescriber decides to adjust the dose based on creatinine clearance. This adjustment is a practical
application of which pharmacokinetic principle?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Half-life
🟢 D. Half-life
PLUS RATIONALES 2026 Q&A | LATEST EXAM UPDATE 2026/2027.
Core Domains:
Pharmacokinetics (ADME)
Pharmacodynamics (Receptor Theory & Dose-Response)
Autonomic Nervous System Pharmacology
Cardiovascular & Renal Pharmacology
Central Nervous System Pharmacology
Endocrine Pharmacology
Antimicrobial & Chemotherapeutic Agents
Toxicology & Adverse Drug Reactions
Pharmacogenomics & Drug Interactions
Legal, Ethical, and Professional Standards in Prescribing
Introduction:
This comprehensive assessment is designed to rigorously evaluate the candidate's mastery of fundamental
pharmacological principles as outlined in the Kaplan Pharmacology I curriculum. The examination measures both
foundational knowledge of drug mechanisms and the application of clinical decision-making in complex patient
scenarios. Through a series of multiple-choice questions and case-based presentations, candidates will be
,challenged to integrate pharmacodynamic and pharmacokinetic concepts with legal, ethical, and professional
standards of care. The emphasis is on real-world application, requiring the candidate to prioritize patient safety,
recognize adverse drug reactions, and formulate evidence-based therapeutic plans. Successful completion of this
assessment demonstrates readiness for advanced clinical practice and standardized examination preparation.
SECTION ONE: QUESTIONS 1–50
1. A patient with a history of chronic liver disease is prescribed a medication with high hepatic extraction.
Which pharmacokinetic parameter is MOST significantly altered in this patient, leading to a marked increase
in drug bioavailability?
A. Volume of distribution
B. Renal clearance
C. First-pass metabolism
D. Plasma protein binding
🟢 C. First-pass metabolism
🔴 RATIONALE: Drugs with high hepatic extraction undergo extensive first-pass metabolism, significantly
reducing their bioavailability. In liver disease, hepatic blood flow and metabolic enzyme function decrease,
reducing this effect and leading to a marked increase in bioavailability. Volume of distribution is more affected
by protein binding and body composition, not directly the primary cause of this increased bioavailability. Renal
clearance primarily affects drugs excreted by the kidneys. While plasma protein binding can be altered, the
primary mechanism for this change in bioavailability is the reduction in first-pass metabolism.
, 2. A new drug is being developed that acts as a non-competitive antagonist at a specific receptor. In the
presence of this drug, which change in the dose-response curve for the endogenous agonist is MOST likely
observed?
A. Parallel shift to the right with no change in maximum effect
B. Non-parallel shift to the right with a decreased maximum effect
C. Parallel shift to the left with no change in maximum effect
D. Non-parallel shift to the right with an increased maximum effect
🟢 B. Non-parallel shift to the right with a decreased maximum effect
🔴 RATIONALE: Non-competitive antagonists bind to an allosteric site on the receptor, effectively reducing the
number of available receptors. This results in a non-parallel shift to the right of the dose-response curve and,
most importantly, a reduction in the maximum achievable effect (Emax). A competitive antagonist (A) causes a
parallel shift to the right with no change in Emax.
3. An 80-year-old patient with renal impairment is prescribed a medication primarily cleared by the kidneys.
The prescriber decides to adjust the dose based on creatinine clearance. This adjustment is a practical
application of which pharmacokinetic principle?
A. Bioavailability
B. Volume of distribution
C. Clearance
D. Half-life
🟢 D. Half-life
